Enlivex Therapeutics (ENLV) Short Interest Ratio & Short Volume $1.24 +0.06 (+5.08%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends Enlivex Therapeutics Short Interest DataEnlivex Therapeutics (ENLV) has a short interest of 214,800 shares. This marks a 116.53% increase in short interest from the previous month. The short interest ratio (days to cover) is 0.9, indicating that it would take 0.9 days of the average trading volume of 145,580 shares to cover all short positions.Current Short Interest214,800 sharesPrevious Short Interest99,200 sharesChange Vs. Previous Month+116.53%Dollar Volume Sold Short$244,872.00Short Interest Ratio0.9 Days to CoverLast Record DateNovember 30, 2024Outstanding Shares21,406,000 sharesPercentage of Shares Shorted1.00%Today's Trading Volume138,306 sharesAverage Trading Volume145,580 sharesToday's Volume Vs. Average95% Short Selling Enlivex Therapeutics? Sign up to receive the latest short interest report for Enlivex Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartENLV Short Interest Over TimeENLV Days to Cover Over TimeENLV Percentage of Float Shorted Over Time Ad Porter & CompanyI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. Here’s the full story for you. Enlivex Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 11/30/2024214,800 shares $244,872.00 +116.5%N/A0.9 $1.14 11/15/202499,200 shares $106,144.00 -38.0%N/A0.7 $1.07 10/31/2024160,100 shares $216,135.00 +58.7%N/A1.4 $1.35 10/15/2024100,900 shares $156,395.00 -3.5%N/A1.1 $1.55 9/30/2024104,600 shares $175,728.00 -23.1%N/A1.4 $1.68 9/15/2024136,100 shares $213,677.00 +43.9%N/A1.9 $1.57 Get the Latest News and Ratings for ENLV and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Enlivex Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 8/31/202494,600 shares $122,980.00 +26.6%N/A1.9 $1.30 8/15/202474,700 shares $91,134.00 -11.7%N/A1.3 $1.22 7/31/202484,600 shares $113,364.00 -27.4%N/A1.4 $1.34 7/15/2024116,500 shares $164,265.00 -0.6%N/A1.6 $1.41 6/30/2024117,200 shares $166,424.00 -16.8%N/A0.7 $1.42 6/15/2024140,800 shares $205,568.00 -10.5%N/A0.8 $1.46 5/31/2024157,300 shares $213,928.00 -31.8%N/A0.9 $1.36 5/15/2024230,600 shares $327,452.00 -12.4%N/A1.3 $1.42 4/30/2024263,200 shares $439,544.00 -5.6%N/A1.5 $1.67 4/15/2024278,700 shares $362,310.00 +17.9%N/A1.6 $1.30 3/31/2024236,400 shares $895,956.00 -9.6%N/A2.7 $3.79 3/15/2024261,500 shares $1.07 million +15.4%N/A2.4 $4.11 2/29/2024226,600 shares $703,593.00 +51.2%N/A2.2 $3.11 2/15/2024149,900 shares $481,179.00 -6.6%N/A1.6 $3.21 1/31/2024160,500 shares $449,400.00 -13.7%N/A1.9 $2.80 1/15/2024185,900 shares $533,533.00 +32.5%N/A2.3 $2.87 12/31/2023140,300 shares $378,810.00 +36.0%N/A1.8 $2.70 12/15/2023103,200 shares $145,512.00 -6.3%N/A1.9 $1.41 11/30/2023110,100 shares $202,584.00 -0.9%N/A3.5 $1.84 11/15/2023111,100 shares $194,425.00 -6.2%N/A3.6 $1.75 10/31/2023118,400 shares $157,472.00 +13.1%N/A3.9 $1.33 10/15/2023104,700 shares $147,627.00 -8.1%N/A4.1 $1.41 9/30/2023113,900 shares $179,962.00 +4.4%N/A4.5 $1.58 9/15/2023109,100 shares $206,199.00 +3.4%N/A4.2 $1.89 8/31/2023105,500 shares $252,145.00 -9.3%N/A4.8 $2.39 8/15/2023116,300 shares $303,543.00 +2.4%N/A5.1 $2.61 7/31/2023113,600 shares $290,816.00 +8.6%N/A4.9 $2.56 7/15/2023104,600 shares $248,948.00 +2.5%N/A4.8 $2.38 6/30/2023102,100 shares $268,247.33 -20.2%N/A3.6 $2.63 6/15/2023128,000 shares $362,240.00 +5.6%N/A3.6 $2.83 5/31/2023121,200 shares $316,332.00 -5.8%N/A3.5 $2.61 5/15/2023128,700 shares $359,073.00 -1.2%N/A3.8 $2.79 4/30/2023130,200 shares $369,768.00 -4.6%N/A3.7 $2.84 4/15/2023136,400 shares $396,924.00 -15.7%N/A3.6 $2.91I was wrong. Dead wrong. (Ad)I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. Here’s the full story for you. 3/31/2023161,700 shares $588,588.00 +0.5%N/A4.3 $3.64 3/15/2023160,900 shares $577,631.00 -1.3%N/A5.9 $3.59 2/28/2023163,000 shares $652,000.00 +0.9%N/A5.7 $4.00 2/15/2023161,500 shares $673,455.00 -8.8%N/A5.5 $4.17 1/31/2023177,100 shares $775,698.00 -2.9%N/A5.8 $4.38 1/15/2023182,300 shares $796,505.16 -4.8%N/A6.9 $4.37 12/30/2022191,400 shares $753,637.50 -0.5%N/A7.8 $3.94 12/15/2022192,400 shares $779,220.00 -11.5%N/A9.2 $4.05 11/30/2022217,500 shares $996,998.25 +16.9%N/A9 $4.58 11/15/2022186,000 shares $894,660.00 +0.1%N/A6.9 $4.81 10/31/2022185,800 shares $797,082.00 -3.8%N/A6.6 $4.29 10/15/2022193,100 shares $805,227.00 +1.2%N/A5.4 $4.17 9/30/2022190,900 shares $811,325.00 +4.5%N/A4.4 $4.25 9/15/2022182,700 shares $959,175.00 -5.4%N/A3.9 $5.25 8/31/2022193,100 shares $1.01 million -7.0%N/A4.2 $5.25 8/15/2022207,700 shares $1.08 million -9.5%N/A4.4 $5.22 7/31/2022229,600 shares $975,800.00 -8.4%N/A4 $4.25 7/15/2022250,600 shares $1.23 million -9.8%N/A3.8 $4.91 6/30/2022277,700 shares $1.26 million -2.3%N/A3.5 $4.52 6/15/2022284,300 shares $1.16 million -0.3%N/A3.5 $4.07 5/31/2022285,000 shares $1.43 million -9.2%N/A3.5 $5.01 5/15/2022313,900 shares $1.34 million -9.6%N/A4.1 $4.28 4/30/2022347,200 shares $1.98 million -3.9%N/A4.7 $5.69 4/15/2022361,300 shares $2.67 million +15.0%N/A5.9 $7.39 3/31/2022314,200 shares $1.76 million -2.2%N/A5.3 $5.59 3/15/2022321,300 shares $1.63 million -10.4%N/A5.3 $5.06 2/28/2022358,500 shares $1.92 million -4.0%N/A4.9 $5.35 2/15/2022373,500 shares $1.99 million +2.8%N/A4.7 $5.34 1/31/2022363,200 shares $1.94 million +8.2%N/A4.2 $5.34 1/15/2022335,700 shares $1.97 million -8.3%N/A3.7 $5.87 12/31/2021365,900 shares $2.29 million +0.1%N/A4.2 $6.25 12/15/2021365,400 shares $2.40 million -3.6%N/A4.4 $6.56 11/30/2021379,000 shares $2.65 million +7.0%N/A5 $7.00 11/15/2021354,200 shares $2.91 million +9.9%N/A3.5 $8.21 10/29/2021322,200 shares $2.65 million +4.5%N/A1 $8.24 10/15/2021308,300 shares $2.86 million -13.0%N/A0.9 $9.28 9/30/2021354,300 shares $3.50 million -8.0%N/A1.1 $9.88 9/15/2021385,200 shares $4.21 million -8.0%N/A1.2 $10.92 8/31/2021418,500 shares $5.80 million +114.2%N/A1.3 $13.86 8/13/2021195,400 shares $1.99 million +38.0%N/A0.7 $10.17 7/30/2021141,600 shares $1.08 million No Change1.2%2.1 $7.60 7/15/2021141,600 shares $1.07 million +0.9%1.2%1.8 $7.54 6/30/2021140,400 shares $1.25 million +4.0%1.2%1.6 $8.90 6/15/2021135,000 shares $1.32 million +14.9%1.1%1.5 $9.80 5/28/2021117,500 shares $1.10 million -28.6%1.0%1.1 $9.37 5/14/2021164,500 shares $1.42 million +26.4%N/A1.1 $8.61 4/30/2021130,100 shares $1.57 million +94.2%N/A0.3 $12.10 4/15/202167,000 shares $725,610.00 -18.8%N/A0.2 $10.83 3/31/202182,500 shares $874,500.00 -17.6%N/A0.2 $10.60 3/15/2021100,100 shares $1.44 million +5.2%1.0%0.2 $14.40I was wrong. Dead wrong. (Ad)I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. Here’s the full story for you. 2/26/202195,200 shares $1.44 million +64.4%1.1%0.2 $15.11 2/12/202157,900 shares $1.22 million -76.6%0.7%0.1 $21.09 1/29/2021246,900 shares $2.93 million +13.8%3.2%0.7 $11.85 1/15/2021217,000 shares $2.23 million +7.1%2.9%1 $10.29 12/31/2020202,600 shares $1.87 million -24.9%2.7%0.7 $9.22 12/15/2020269,700 shares $2.65 million +165.2%3.5%0.2 $9.83 11/30/2020101,700 shares $876,654.00 -38.2%1.3%0.1 $8.62 11/15/2020164,600 shares $1.53 million -13.1%2.2%0.1 $9.28 10/30/2020189,500 shares $2.23 million -53.7%2.5%0.2 $11.75 10/15/2020408,900 shares $5.41 million +1,497.3%5.4%0.4 $13.23 9/30/202025,600 shares $152,064.00 +22.5%0.3%0 $5.94 9/15/202020,900 shares $108,262.00 -57.1%0.3%0.3 $5.18 8/31/202048,700 shares $252,753.00 +429.4%0.6%0.5 $5.19 8/14/20209,200 shares $48,668.00 -59.1%0.1%0.1 $5.29 7/31/202022,500 shares $122,850.00 +10.3%0.3%0.2 $5.46 7/15/202020,400 shares $104,040.00 +88.9%0.3%0.2 $5.10 6/30/202010,800 shares $65,448.00 -6.1%0.1%0.1 $6.06 6/15/202011,500 shares $62,560.00 -48.0%0.2%0.1 $5.44 5/29/202022,100 shares $117,130.00 +71.3%0.3%0.2 $5.30 5/15/202012,900 shares $62,178.00 +152.9%0.2%0.1 $4.82 4/30/20205,100 shares $27,999.00 -67.1%0.1%0 $5.49 4/15/202015,500 shares $86,800.00 -17.6%0.2%0.1 $5.60 3/31/202018,800 shares $105,468.00 -69.6%0.3%0.1 $5.61 3/13/202061,900 shares $282,264.00 +302.0%1.4%0.2 $4.56 2/28/202015,400 shares $63,448.00 -54.0%0.3%0.1 $4.12 2/14/202033,500 shares $192,960.00 +805.4%0.8%0.5 $5.76 1/31/20203,700 shares $31,450.00 -32.7%0.1%0.2 $8.50 1/15/20205,500 shares $45,100.00 +10.0%0.1%0.2 $8.20 12/31/20195,000 shares $45,500.00 +11.1%0.1%0.1 $9.10 ENLV Short Interest - Frequently Asked Questions What is Enlivex Therapeutics' current short interest? Short interest is the volume of Enlivex Therapeutics shares that have been sold short but have not yet been closed out or covered. As of November 30th, investors have sold 214,800 shares of ENLV short. Learn More on Enlivex Therapeutics' current short interest. What is a good short interest ratio for Enlivex Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. ENLV shares currently have a short interest ratio of 1.0. Learn More on Enlivex Therapeutics's short interest ratio. Is Enlivex Therapeutics' short interest increasing or decreasing? Enlivex Therapeutics saw a increase in short interest in the month of November. As of November 30th, there was short interest totaling 214,800 shares, an increase of 116.5% from the previous total of 99,200 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Enlivex Therapeutics' short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Enlivex Therapeutics: Skye Bioscience, Inc. (9.05%), Pyxis Oncology, Inc. (14.79%), Century Therapeutics, Inc. (8.35%), Cellectis S.A. (0.24%), Tonix Pharmaceuticals Holding Corp. (0.85%), Oramed Pharmaceuticals Inc. (0.74%), Scilex Holding (4.77%), Genenta Science S.p.A. (0.01%), Milestone Pharmaceuticals Inc. (0.86%), Tiziana Life Sciences Ltd (0.30%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: AppLovin Co. ($5.70 billion), Charter Communications, Inc. ($4.55 billion), Spotify Technology S.A. ($3.84 billion), Royal Caribbean Cruises Ltd. ($3.07 billion), International Paper ($3.00 billion), Coinbase Global, Inc. ($2.93 billion), Cencora, Inc. ($2.54 billion), Paychex, Inc. ($2.53 billion), SoFi Technologies, Inc. ($2.24 billion), and Reddit, Inc. ($2.00 billion). View all of the most shorted stocks. What does it mean to sell short Enlivex Therapeutics stock? Short selling ENLV is an investing strategy that aims to generate trading profit from Enlivex Therapeutics as its price is falling. ENLV shares are trading up $0.06 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Enlivex Therapeutics? A short squeeze for Enlivex Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of ENLV, which in turn drives the price of the stock up even further. How often is Enlivex Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ENLV, twice per month. The most recent reporting period available is November, 30 2024. More Short Interest Resources from MarketBeat Related Companies Skye Bioscience Short Squeeze Pyxis Oncology Short Squeeze Century Therapeutics Short Squeeze Cellectis Short Squeeze Tonix Pharmaceuticals Short Squeeze Oramed Pharmaceuticals Short Squeeze Scilex Short Squeeze Genenta Science Short Squeeze Milestone Pharmaceuticals Short Squeeze Tiziana Life Sciences Short Squeeze Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:ENLV) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTop Picks for Trump’s Pro-Crypto AmericaCoins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enlivex Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enlivex Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
